Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With Anthracyclines

This study is using a new type of CT scan called Spectral CT to monitor heart health in people receiving chemotherapy (specifically anthracyclines) for Hodgkin's lymphoma or diffuse large B-cell lymphoma. Some chemotherapy drugs can damage the heart over time, and this study wants to detect that damage earlier and more accurately. **You may be eligible if...** - You are 18 years or older - You have Hodgkin's lymphoma or diffuse large B-cell lymphoma - You are receiving a chemotherapy regimen that includes anthracyclines (drugs like doxorubicin) **You may NOT be eligible if...** - You cannot receive CT contrast dye (e.g., severe kidney disease, pregnancy) - You have a history of heart disease (heart attack, heart failure, arrhythmia, cardiomyopathy, prior heart inflammation) - You have previously had radiation therapy to the chest area Talk to your doctor to see if this trial is right for you.